Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.85 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Benzylamphetamine SCHEMBL2795222 | 0.92 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| N-Benzylamphetamine SCHEMBL2451256 | 0.92 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| N-Benzylamphetamine SCHEMBL2798189 | 0.92 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| N-Benzylamphetamine SCHEMBL8085021 | 0.90 | SIGMAR1 (0.96) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| SCHEMBL608555 | 0.87 | SIGMAR1 (0.82) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| SCHEMBL8092729 | 0.87 | SIGMAR1 (0.82) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| SCHEMBL24997843 | 0.86 | SIGMAR1 (0.79) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| SCHEMBL10005270 | 0.86 | SIGMAR1 (0.79) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| SCHEMBL3235181 | 0.86 | SIGMAR1 (0.79) | SIGMAR1TAAR1SLC18A2LMNAPOLB | |
| SCHEMBL8091283 | 0.86 | SIGMAR1 (0.79) | SIGMAR1TAAR1SLC18A2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | SIGMAR1 3129/4885TAAR1 2357/4885SLC18A2 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.